Role of Ga-68 Somatostatin Receptor PET/CT in the Assessment of Response to Radiofrequency Ablation in Hepatic Metastases of Neuroendocrine Tumors

#563

Introduction: Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) present frequently with hepatic metastases. Radiofrequency ablation (RFA) is an important local ablative treatment for hepatic metastases.

Aim(s): To evaluate the role of Ga-68 somatostatin receptor PET/CT (SSTR PET/CT) in the assessment of response to RFA in hepatic metastases of NET in comparison with the other radiological imaging modalities.

Materials and methods: Ten patients of known GEP-NET underwent RFA (in total of 17 segments) for hepatic metastases. All patients had undergone SSTR PET/CT using Ga-68 DOTATOC, 4-phase CT, MRI and USG before, and 3-6 months after RFA.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Petrovich A, Hoersch D, Baum R,

Keywords: Somatostatin Receptor PET/CT, radiofrequency ablation, hepatic metastases,